News Year None202020192018 September 17, 2020 Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020 September 15, 2020 Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients September 3, 2020 Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference August 18, 2020 Equillium Announces Closing of Public Offering of Common Stock August 13, 2020 Equillium Announces Pricing of Public Offering of Common Stock August 13, 2020 Equillium Announces Proposed Public Offering of Common Stock August 12, 2020 Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights August 10, 2020 Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study July 30, 2020 Equillium to Present at BTIG Virtual Biotechnology Conference 2020 July 13, 2020 Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
September 17, 2020 Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
September 15, 2020 Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
July 13, 2020 Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
